Trial · NCT02269267
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | Less or equal to one month | 0 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | One month to two months | 4 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | Two months to three months | 12 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | Three months to four months | 11 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | Four months to five months | 7 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | Five months to six months | 5 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | Six months to eight months | 2 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | Eight months to 10 months | 3 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | Ten months to 12 months | 4 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | 12 months to 14 months | 2 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | 14 months to 16 months | 2 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | 16 months to 18 months | 1 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | 18 months to 20 months | 0 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | 20 months to 22 months | 0 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | 22 months to 24 months | 1 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | 24 months to 27 months | 1 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | 27 months to 30 months | 2 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | 30 months to 33 months | 0 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | 33 months to 36 months | 0 | Participants | |
| Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. | Discontinuation of TKI Medication | 36 months | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02269267/results